Glomerulonephritis Market to Accelerate Substantially During the Forecast Period (2022-32) – DelveInsight | Otsuka, AstraZeneca, Novartis, Alnylam, Apellis Pharmaceuticals, Omeros Corporation
DelveInsight’s “Glomerulonephritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glomerulonephritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Glomerulonephritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Glomerulonephritis: An Overview
Glomerulonephritis (GN), also known as nephritis or nephrotic syndrome, is a group of diseases that injure the part of the kidney that filters blood (called glomeruli). When the kidney is injured, it cannot get rid of wastes and extra fluid in the body. If the illness continues, the kidneys may stop working completely, resulting in kidney failure. Glomerulonephritis often comes to light when a routine urinalysis is abnormal. Tests to assess kidney function and diagnose Glomerulonephritis include urine tests, blood tests, imaging tests, and kidney biopsies.
Glomerulonephritis treatment depends on the form of the disease, underlying cause, type, and severity of signs and symptoms.
Glomerulonephritis Market Key Facts
-
As per the study by Kazi et al. (2020), Glomerulonephritis is a prominent cause of renal impairment. It leads to 10 to 15% of end-stage renal disease cases in the US. In most instances, the disease becomes progressive without timely intervention, eventually leading to morbidity.
-
As per the DelveInsight, in the 7MM, Glomerulonephritis (GN) affects males more than females.
The Glomerulonephritis market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Glomerulonephritis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Glomerulonephritis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Glomerulonephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Glomerulonephritis Epidemiology Segmentation
-
Prevalent Population of Glomerulonephritis (GN)
-
Gender-specific Prevalent Population of Glomerulonephritis (GN)
-
Diagnosed and Treatable Cases of Glomerulonephritis (GN)
Glomerulonephritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glomerulonephritis market or expected to get launched during the study period. The analysis covers Glomerulonephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glomerulonephritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Glomerulonephritis Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/glomerulonephritis-market
Glomerulonephritis Therapeutics Analysis
The pipeline of Glomerulonephritis (GN) possesses several mid-phase potential therapies developed by key pharma and biotech companies at the global level. The launch of emerging therapies is expected during the forecast period.
Some of the key companies in the Glomerulonephritis Market include:
-
Otsuka
-
AstraZeneca
-
Novartis Pharmaceuticals
-
Alnylam Pharmaceuticals
-
Apellis Pharmaceuticals
-
Omeros Corporation
And many others
Glomerulonephritis Therapies covered in the report include
-
APL-2
-
VIS649
-
OMS721
-
AZD2373
-
Iptacopan (LNP023)
-
Cemdisiran (ALN-CC5)
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More-
https://www.delveinsight.com/sample-request/glomerulonephritis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Glomerulonephritis Competitive Intelligence Analysis
4. Glomerulonephritis Market Overview at a Glance
5. Glomerulonephritis Disease Background and Overview
6. Glomerulonephritis Patient Journey
7. Glomerulonephritis Epidemiology and Patient Population (In US, EU5, and Japan)
8. Glomerulonephritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Glomerulonephritis Unmet Needs
10. Key Endpoints of Glomerulonephritis Treatment
11. Glomerulonephritis Marketed Products
12. Glomerulonephritis Emerging Drugs and Latest Therapeutic Advances
13. Glomerulonephritis Seven Major Market Analysis
14. Attribute Analysis
15. Glomerulonephritis Market Outlook (In US, EU5, and Japan)
16. Glomerulonephritis Access and Reimbursement Overview
17. KOL Views on the Glomerulonephritis Market
18. Glomerulonephritis Market Drivers
19. Glomerulonephritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/glomerulonephritis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Candidiasis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Candidiasis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
